# bioAffinity Technologies, Inc. (BIAF) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BIAF
## Company Profile
- Ticker: BIAF
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: Diagnostics, Oncology
## Stock Data
- Close: 0.5298 USD
- Market cap: 7618642.08 USD
- Last updated: 2026-08-05
## Business Overview
### Noninvasive Lung Diagnostics
bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease. Its approach uses flow-cytometry and artificial-intelligence analysis of cells collected from sputum samples.
### CyPath Lung
CyPath Lung is a laboratory-developed test intended to help assess patients at elevated risk of lung cancer, including those with indeterminate imaging findings. It is positioned between imaging surveillance and invasive diagnostic procedures. The company is also exploring applications of its cellular-analysis platform in asthma and chronic obstructive pulmonary disease, including potential companion-diagnostic uses.
## Why The Stock Is Moving

The latest monitored company update is “bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- bioAffinity’s catalysts are lung-cancer screening adoption and any update that clarifies whether the diagnostics platform can scale. The company still needs a stronger commercial runway.

## Recent News
- 2026-08-07 12:00 EST — [bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-second-quarter-2026-results-and-continued-stron-0f0ca732) — Source: bioAffinity Technologies, Inc.
- 2026-07-27 12:08 EST — [bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-publishes-new-clinical-framework-addressing-growing-mar-0496e8ef) — Source: bioAffinity Technologies, Inc.
- 2026-07-22 12:08 EST — [bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-and-pictor-inc-partner-to-develop-and-commercialize-bio-7ee819d4) — Source: bioAffinity Technologies, Inc.
- 2026-07-07 12:46 EST — [bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-quarterly-cypath-lung-sales-double-to-new-record-as-com-fee483fe) — Source: bioAffinity Technologies, Inc.
- 2026-06-22 12:00 EST — [bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-positive-preclinical-findings-showing-proprieta-c62b401e) — Source: bioAffinity Technologies, Inc.